Stockwatch: Hopping on and off the inversion train
This article was originally published in Scrip
As we move another week closer to the US Congressional mid–term elections, the prospect of any real legislative interruption to the life science inversion train continues to diminish. Inversions are where pharmaceutical and specialty pharmaceutical companies buy smaller foreign rivals to gain, amongst other advantages, their target's lower tax rate on the combined company's total profits.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.